EOM-613 is under clinical development by EOM Pharmaceuticals and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome. According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EOM-613’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

EOM-613 overview

EOM-613 (OHR118/AVR118) is under development for the treatment of coronavirus disease 2019 (COVID-19) associated acute respiratory distress syndrome caused by coronavirus disease 2019 (COVID-19), associated cytokine release syndrome and crohn's disease. The drug candidate is administered subcutaneously. It is a broad-spectrum peptide nucleic acid immunomodulator drug which modulates cytokine action. OHR118/AVR118 was under development for the treatment of cancer cachexia, metastatic breast cancer, leukemias and advanced malignancy, AIDS cachexia and rheumatoid arthritis.

EOM Pharmaceuticals overview

EOM Pharmaceuticals (EOM Pharma), formerly ImmunoCellular Therapeutics is a clinical-stage biotechnology company which develops immune-based therapies for the treatment of various cancers. The product pipeline of the company includes active immunotherapies and patented monoclonal antibodies. EOM Pharma’s immunotherapies product pipeline comprises ICT-107, ICT-140 and ICT-121. ICT-107, the lead product candidate of the company is being developed for the treatment of glioblastoma multiforme (GBM); ICT-140, a DC vaccine designed to treat recurrent ovarian cancer; and ICT-121 for the treatment of recurrent GBM and other solid tumors. The company also develops stem cell therapies for treating cancer. As of March 2015, the development of ICT-140 has been put on hold. EOM Pharma is headquartered in Calabasas, California, the US.

For a complete picture of EOM-613’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.